Briacell Therap (NASDAQ:BCTX) Posts Earnings Results, Beats Estimates By $7.76 EPS

by · The Cerbat Gem

Briacell Therap (NASDAQ:BCTX – Get Free Report) announced its earnings results on Thursday. The company reported ($4.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($12.11) by $7.76, Zacks reports.

Briacell Therap Trading Down 8.8%

Shares of BCTX traded down $1.00 during mid-day trading on Thursday, reaching $10.31. The company’s stock had a trading volume of 84,870 shares, compared to its average volume of 100,453. Briacell Therap has a 52 week low of $6.00 and a 52 week high of $106.50. The company’s fifty day moving average price is $11.09 and its two-hundred day moving average price is $14.81. The stock has a market cap of $19.42 million, a PE ratio of -0.12 and a beta of 1.38.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $320.00.

Get Our Latest Analysis on BCTX

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 15.42% of the company’s stock.

About Briacell Therap

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

Featured Articles